Endoglin (CD105) is a 90 kDa type I transmembrane glycoprotein of the zona pellucida (ZP) family of proteins. Endoglin is highly expressed on proliferating vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta, with lower amounts on hematopoietic, mesenchymal and neural crest stem cells, activated monocytes, and lymphoid and myeloid leukemic cells. Endoglin homodimers interact with TGF‑ beta 1 and TGF‑ beta 3 (but not TGF‑ beta 2), but only after binding T beta RII. Similarly, they interact with activin‑A and BMP‑7 via activin type IIA or B receptors, and with BMP‑2 via BMPR‑1A/ALK‑3 or BMPR‑1B/ALK‑6. BMP‑9, however, is reported to bind endoglin directly. Endoglin modifies ligand‑induced signaling in multiple ways. For example, expression of endoglin can inhibit TGF‑ beta 1 signals but enhance BMP7 signals in the same myoblast cell line. In endothelial cells, endoglin inhibits T beta RI/ALK5, but enhances ALK1‑mediated activation.

高纯度、高活性、低内毒素、高批间一致性

产品数据

-25 ~ -15℃保存，收到货之后有效期1年。 复溶后， 无菌条件下，-85 ~ -65℃保存，3个月有效期。